000132438 001__ 132438
000132438 005__ 20250923084416.0
000132438 0247_ $$2doi$$a10.3389/fimmu.2024.1289303
000132438 0248_ $$2sideral$$a137568
000132438 037__ $$aART-2024-137568
000132438 041__ $$aeng
000132438 100__ $$0(orcid)0000-0001-9262-2461$$aMorte-Romea, Elena$$uUniversidad de Zaragoza
000132438 245__ $$aCAR immunotherapy for the treatment of infectious diseases: a systematic review
000132438 260__ $$c2024
000132438 5060_ $$aAccess copy available to the general public$$fUnrestricted
000132438 5203_ $$aImmunotherapy treatments aim to modulate the host’s immune response to either mitigate it in inflammatory/autoimmune disease or enhance it against infection or cancer. Among different immunotherapies reaching clinical application during the last years, chimeric antigen receptor (CAR) immunotherapy has emerged as an effective treatment for cancer where different CAR T cells have already been approved. Yet their use against infectious diseases is an area still relatively poorly explored, albeit with tremendous potential for research and clinical application. Infectious diseases represent a global health challenge, with the escalating threat of antimicrobial resistance underscoring the need for alternative therapeutic approaches. This review aims to systematically evaluate the current applications of CAR immunotherapy in infectious diseases and discuss its potential for future applications. Notably, CAR cell therapies, initially developed for cancer treatment, are gaining recognition as potential remedies for infectious diseases. The review sheds light on significant progress in CAR T cell therapy directed at viral and opportunistic fungal infections.
000132438 536__ $$9info:eu-repo/grantAgreement/ES/AEI/PID2020-113963RB-I00$$9info:eu-repo/grantAgreement/ES/AEI/RYC2022-036627-I$$9info:eu-repo/grantAgreement/ES/DGA/B29-23R$$9info:eu-repo/grantAgreement/ES/DGA/LMP39_21$$9info:eu-repo/grantAgreement/ES/ISCIII/CB21-13-00087
000132438 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000132438 590__ $$a5.9$$b2024
000132438 592__ $$a1.941$$b2024
000132438 591__ $$aIMMUNOLOGY$$b32 / 183 = 0.175$$c2024$$dQ1$$eT1
000132438 593__ $$aImmunology and Allergy$$c2024$$dQ1
000132438 593__ $$aImmunology$$c2024$$dQ1
000132438 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000132438 700__ $$aPesini, Cecilia
000132438 700__ $$aPellejero-Sagastizábal, Galadriel$$uUniversidad de Zaragoza
000132438 700__ $$aLetona-Giménez, Santiago
000132438 700__ $$0(orcid)0000-0003-3043-147X$$aMartínez-Lostao, Luis$$uUniversidad de Zaragoza
000132438 700__ $$aLoscos Aranda, Silvia
000132438 700__ $$0(orcid)0000-0002-4217-6317$$aToyas, Carla
000132438 700__ $$aRedrado, Sergio
000132438 700__ $$aDolader-Ballesteros, Elena$$uUniversidad de Zaragoza
000132438 700__ $$aArias, Maykel
000132438 700__ $$aGalvez, Eva M.
000132438 700__ $$aSanz-Pamplona, Rebeca
000132438 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, Julián$$uUniversidad de Zaragoza
000132438 700__ $$0(orcid)0000-0002-9600-8116$$aPaño-Pardo, Jose Ramón$$uUniversidad de Zaragoza
000132438 700__ $$0(orcid)0000-0002-3888-7036$$aRamírez-Labrada, Ariel
000132438 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000132438 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000132438 773__ $$g15 (2024), 1289303 [13 pp.]$$pFront. immunol.$$tFrontiers in Immunology$$x1664-3224
000132438 8564_ $$s2887353$$uhttps://zaguan.unizar.es/record/132438/files/texto_completo.pdf$$yVersión publicada
000132438 8564_ $$s2153197$$uhttps://zaguan.unizar.es/record/132438/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000132438 909CO $$ooai:zaguan.unizar.es:132438$$particulos$$pdriver
000132438 951__ $$a2025-09-22-14:33:00
000132438 980__ $$aARTICLE